What service do you need? Contact Request

NCT07779642

Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory Failure

← Clinical trials hub

Registry fields

Overall status: NOT_YET_RECRUITING
Conditions: ARDS (Acute Respiratory Distress Syndrome), Acute Hypoxic Respiratory Failure
Study type: INTERVENTIONAL
Phase: PHASE2
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: Simvastatin, Baricitinib
Lead sponsor: University of Colorado, Denver (OTHER)

Cached at: 2026-10-09 04:11:07

View on ClinicalTrials.gov

Brief summary

The goal of this trial is to accelerate the development of pharmacological therapies for critical illness by identifying biological sub phenotypes in patients with acute respiratory distress syndrome (ARDS). The trial will stratify participants by biological markers into different sub phenotypes, then randomized 1:1:1 to active treatment 1, active treatment 2, or usual care. Initial stratification will be into hyperinflammatory and hypoinflammatory sub phenotypes in ARDS based on plasma biomarker profiles. Regular adaptive analyses will enable efficient identification of treatment effects within each sub phenotype, stopping interventions where there is evidence of efficacy or futility, and bringing in new interventions and potentially new sub phenotypes.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report